Skip to main content

Table 1 Patient and tumor characteristics

From: RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families

   non-BRCA1/2(n = 70) BRCA1 (n = 33) BRCA2 (n = 22) Sporadic (n = 128)
Estrogen receptor      
  ER+ 8.6% 42.4% 90.9% 83.6%
  ER- 21.4% 57.6% 9.1% 16.4%
Progesterone receptor      
  PR+ 65.7% 21.2% 72.7% 61.7%
  PR- 34.3% 78.8% 27.3% 38.3%
HER2 status      
  HER2+ 14.3% 9.1% 4.5% 16.4%
  HER2- 85.7% 90.1% 95.5% 83.6%
Lymph node      
  LN+ 41.4% 45.5% 63.6% 39.8%
  LN- 52.9% 48.5% 31.8% 58.6%
  NA 5.7% 6.1% 4.5% 1.6%
Tumor size      
  Mean tumor size, mm [±SD] 25 [±18] 23 [±10] 25 [±13] 25 [±16]
Histologic grade      
  Grade 1 17.1% 9.1% 9.1% 25.0%
  Grade 2 40% 21.2% 50.0% 37.5%
  Grade 3 28.6% 54.5% 31.8% 22.7%
  NA 14.3% 15.2% 9.1% 14.8%
Tumor type      
  Invasive ductal carcinoma 78.6% 84.8% 86.4 % 82.0%
  Invasive lobular carcinoma 12.9% 3.0% 9.1 % 9.4%
  Mucinous carcinoma - - - 1.6%
  Medullary carcinoma 1.4 % 6.1% - 0.8%
  Tubular carcinoma - - - 2.3%
  Metaplastic carcinoma 1.4 % - - -
  Other - 6.1 % - 1.6%
  NA 5.7 % - 4.5% 2.3%
Age      
  Median age, years [range] 50 [29–86] 42 [25–74] 43.5 [28–72] 61 [27–95]
  < 50 years 47.1% 63.6% 68.2% 16.4%
  ≥ 50 years 52.9% 36.4% 31.8% 83.6%
Menupause status      
  Premenopausal 52.9% 60.6% 68.2% 23.4%
  Perimenopausal 2.9% - 4.5% 11.7%
  Postmenopausal 38.6% 36.4% 22.7% 60.9%
  Other 2.9% - - 1.6%
  NA 2.9% 3.0% 4.5% 2.3%